Abstract: TH-OR065
Zuberitamab Therapy in Primary Membranous Nephropathy: A Multicenter Prospective Cohort Study
Session Information
- Glomerular Diseases: Epidemiology and Real-World Outcomes
October 22, 2026 | Location: Room 501, Convention Center
Abstract Time: 04:40 PM - 04:50 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- He, Qiang, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China
- Fu, Lanjun, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China
- Li, Hua, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
- Chen, Zhejun, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China
- Chen, Chaosheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
- Huang, Jiancheng, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
- Huang, Jian, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, China
- Li, Yiwen, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
- Shen, Shuijuan, Shaoxing People's Hospital, Shaoxing, Zhejiang, China
- Shi, Zhanqin, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China
- Wu, Henglan, First Hospital of Jiaxing, Jiaxing, Zhejiang, China
- Li, Chunping, Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, China
- Jin, Lie, Lishui Central Hospital, Lishui, Zhejiang, China
- Ning, Zhao, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
- Bu, Shuangshan, Dongyang People's Hospital, Dongyang, Zhejiang, China
- Ma, Kun Ling, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Background
Primary membranous nephropathy (MN) is driven by autoreactive B cells producing antiPLA2R antibodies. Zuberitamab is a novel antiCD20 monoclonal antibody, enhancing CD20 binding affinity and antibody dependent cellular cytotoxicity (ADCC). This study evaluated the efficacy and safety of zuberitamab in patients with primary MN.
Methods
This prospective study enrolled 100 adult patients with PLA2R associated primary MN (60 treatment naïve, 40 refractory/relapsed) across 14 centers in China. Zuberitamab was given intravenously at 1000 mg on Days 0 and 14; optional doses at Months 3 and 6 were permitted based on treatment response. The primary endpoint was overall remission at Week 52.
Results
Overall clinical remission rates increased progressively: 32.9% (29/88) at Week 12, 51.0% (26/51) at Week 24, and 65.0% (13/20) at Week 36. Treatment naïve patients showed numerically higher remission rates than refractory/relapsed patients (51.9% vs. 50.0% at Week 24; 72.7% vs. 55.6% at Week 36), suggesting a favorable trend over time. Rapid B cell depletion (CD19 cells declined from 159/μL to undetectable) was accompanied by a marked reduction in anti-PLA2R levels from 101.5 to 3.6 RU/mL by Week 6). By Week 24, 90.2% achieved immunologic remission (<14 RU/mL). Safety was excellent: adverse events occurred in only 7.9% of patients, and infusion related reactions in 2.0%, lower than reported for other anti CD20 monoclonal antibody. Key laboratory parameters showed consistent improvement (see Table; *P< 0.05, #P< 0.01, $P< 0.001).
Conclusion
Zuberitamab induced progressive clinical remission, with rapid B cell depletion and sustained reduction in anti PLA2R antibodies. It demonstrated broad efficacy across subgroups and a favorable safety profile, supporting its potential as a promising therapy for primary MN.